Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Genzyme Stories

2012-02-29 06:00:00

CARLSBAD, Calif., Feb. 29, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced its 2011 financial results and reviewed the highlights of the year. Isis finished 2011 with a pro forma net operating loss (NOL) of $61.3 million compared to a pro forma NOL of $36.2 million for 2010. The Company finished 2011 with nearly $344 million in cash. On a GAAP basis, Isis reported a loss from operations of $18.6 million and $71.1 million for the three and twelve months ended...

2012-02-08 06:00:00

PARIS, Feb. 8, 2012 /PRNewswire/ -- (Logo : http://photos.prnewswire.com/prnh/20110616/NY20158LOGO ) Change at Change at Q4 2011 Change on a constant 2011 Change on a constant ------- ----------- --------- ---- ----------- --------- reported...

2012-01-23 03:59:00

LONDON, January 23, 2012 /PRNewswire/ -- Representatives of Swiss, EMA, US Pharmacopoeia and WHO will discuss the new regulatory landscape as well as provide the feedback from recent inspections of pharmaceutical manufacturers at 11th Annual Cool Chain Logistics Europe, 30 January - 01 February 2012 in Basel, Switzerland. Over 400 attendees including senior representatives from : Novo Nordisk, Genzyme, Pfizer, Abbott, Pliva, Amgen, Bayer, GlaxoSmithKline, Johnson &...

2012-01-05 07:46:00

BRIDGEWATER, N.J., Jan. 5, 2012 /PRNewswire/ -- Sanofi US today announced that the U. S. District Court in Massachusetts granted the company a preliminary injunction against a Synvisc-One(®) (hylan G-F 20) competitor product developed by Seikagaku Corporation. The ruling allows for a restricted launch of Seikagaku's product prior to a scheduled trial date in April, and prohibits Seikagaku from selling their product below the current average sales price for Synvisc-One....

2012-01-03 08:00:00

NOVATO, Calif., Jan. 3, 2012 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9, 2012 at 11:30 a.m. PT. Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the...

2012-01-03 08:00:00

NOVATO, Calif., Jan. 3, 2012 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that the Investigational New Drug (IND) application for BMN-111, an analog of C-type Natriuretic Peptide (CNP), for achondroplasia is active. The company expects to initiate the Phase 1 trial in the first quarter of 2012. "BMN-111 has demonstrated benefits in moderately and severely affected animal models and has been shown to promote bone growth even in normal animals," stated Hank...

2011-12-22 06:31:00

CAMBRIDGE, Mass., Dec. 22, 2011 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration), the only biopharmaceutical company focused exclusively on the development and commercialization of new treatment options for people with hemophilia, announced today that the Company has expanded its leadership team with four key hires. Howard Levy, M.D., Ph.D. has joined Inspiration as Chief Medical Officer; Daniel Regan as Chief Commercial Officer; Nikki Hadas as General...

2011-11-30 15:00:00

NOVATO, Calif., Nov. 30, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that it has completed the buy back of certain intellectual property from SA Pathology, a unit of the Central Adelaide Local Health Network located in Adelaide, Australia for an upfront payment of $81 million. The intellectual property includes patents related to the purified form of Naglazyme and the method of using the enzyme in the treatment of MPS VI, which expire between...

2011-11-29 15:00:00

NOVATO, Calif., Nov. 29, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 2 study for GALNS (N-acetylgalactosamine 6-sulfatase) in patients under five years of age with mucopolysaccharidosis IVA (MPS IVA). "We expect this study to build our knowledge base in enzyme replacement therapies wherein clinicians believe earlier therapy is more impactful," said Hank Fuchs, M.D., Chief Medical Officer of BioMarin. "Comparatively speaking,...

2011-11-03 08:00:00

NOVATO, Calif., Nov. 3, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development at BioMarin, will present a company update at the Credit Suisse Healthcare Conference in Phoenix on Thursday, November 10, 2011 at 3:30 p.m. MST. Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on...